Motley Bio

Motley Bio leverages its proprietary multi-omic sequencing technology to simultaneously profile DNA, RNA, and proteins (multi-omics) with a single assay producing a single readout, targeting applications in drug discovery, biomarker identification, and early cancer detection for biotech and pharmaceutical companies. Th

Motley Bio is a business in cancer.

Profile

Motley Bio leverages its proprietary multi-omic sequencing technology to simultaneously profile DNA, RNA, and proteins (multi-omics) with a single assay producing a single readout, targeting applications in drug discovery, biomarker identification, and early cancer detection for biotech and pharmaceutical companies. The company sets itself apart by providing richer, more comprehensive data (single assay instead of […]

Within the cancer space, the company focuses on its core offering rather than a broad product line.

Directory data places it at the Creative Destruction Lab alumni company stage.

Website: motleybio.github.io